How to prepare a pediatric study deferral request

What makes a pediatric study deferral request credible?

Identify the retained pediatric obligation, age groups and reason the evidence will follow approval. Build proposed milestones from the scientific and operational dependencies, with evidence of diligent work. For an extension, reconcile the actual existing deadline, progress, delay and revised plan. Keep the requested schedule distinct from the deadline FDA has granted.

Before you begin

PREA deferral and related extension preparation for a defined pediatric program.

What you will prepare: A scoped request with a justified reason, documented study plan and accountable delivery milestones.

Explain why later delivery is justified

Start with the assessments or investigation that would otherwise be due, the age groups and the intended marketing application. A deferral retains the obligation to provide the evidence. It is not a waiver, an automatic consequence of adult development, or an extension obtained merely by asking.

The final iPSP guidance V.B.5 describes deferral grounds such as adult approval readiness before pediatric study completion, a need for additional safety or effectiveness information before pediatric work, or another appropriate reason. Identify the actual dependency. Explain which missing information changes safe or scientifically sound pediatric development and when it is expected.

Write the schedule from evidence-producing activities

For each deferred study, list the population, objective, formulation dependency, protocol readiness, planned initiation, completion and report-submission milestone. Link timing to real activities: formulation manufacture, analytical work, juvenile studies when relevant, feasibility/site work, recruitment, follow-up and analysis. State which dates are proposed and which were agreed with FDA.

The request should connect the grounds for deferral to the evidence that studies will be pursued diligently and as early as feasible. Assign owners to critical dependencies and describe contingencies. Do not insert an attractive completion date that the clinical operations and formulation teams cannot support.

For an extension request, reproduce the current due date, the milestone history, the reason for delay, actions already taken and a revised plan. Provide records of effort rather than simply saying recruitment was difficult. Establish the applicable request timing and procedure with the regulatory owner before a deadline is missed.

Keep progress reporting and the decision record connected

Compare the requested dates with the iPSP, approval letter, subsequent FDA correspondence and postmarketing requirement register. Update those controlled records only to the status actually established. A submitted extension is not an agency-approved revised deadline.

Public Law 119-75 section 6602 changed PREA enforcement provisions and contains its own transition rule. Do not copy obsolete statements that PREA failures can never lead to the specified section 303 action. Have the regulatory/legal owner review a missed deadline or noncompliance letter using the current law and actual diligence evidence. The change to section 6601's future application scope is a different timing question.

Worked review: the new date does not solve the bottleneck

Fictional editorial exercise: a formulation study is delayed six months. The author shifts the final report date by two months without changing recruitment assumptions or explaining overlapping work.

Rebuild the dependency timeline with the responsible teams and document any scientifically justified overlap. If the FDA-agreed deadline cannot be located, recover the letter before labeling the request an extension. The useful outcome is a defensible revised schedule and a clear request, not a promise that FDA will accept it.

Build the request around the work that controls delivery

A date change is persuasive only when the underlying work is understood. Use a dependency record with evidence, owner and a proposed completion date for each relevant activity. This is an internal planning aid, not a substitute for the required study plan or justification.

Schedule exercise: the formulation will be ready later than planned. The draft moves enrollment and report submission by the same short interval but leaves no time for required follow-up. Rebuild the sequence from formulation readiness through enrollment, follow-up, analysis and final reporting. Identify activities that can proceed concurrently, but do not shorten a scientific observation period merely to fit a preferred deadline.

An extension narrative should distinguish the event causing delay, when it became known, why the existing plan could not absorb it, action already taken and the remaining constraint. “Recruitment was difficult” is too broad to explain the problem. The May 2023 draft discusses supporting recruitment evidence such as sites contacted and participants screened and enrolled. Use those as practical examples, while preserving the document’s draft status and checking the applicable statutory request timing before submission.

The final iPSP guidance says the pediatric development timeline should rest on clinical, scientific and operational considerations, independently of an anticipated application or approval date. Some preparatory work can begin before adult approval. Distinguish a justified dependency from a business decision to postpone all pediatric activity.

Keep a dated diligence record: action, evidence, result, next step and owner. If a deadline is missed or a noncompliance letter arrives, the 2026 law’s due-diligence provisions and transition require their own assessment. Neither that record nor a submitted extension establishes FDA agreement to a later deadline. The law's three-year oncology application provision and its separate enforcement transition are different rules.

Reconcile the request with the agreed pediatric plan and the annual postmarketing-study status report. An annual update explains progress; it does not grant an extension.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides